Skip to main content
Search form
Search
Medicines for Malaria Venture
Developing antimalarials to save lives
Research & Development
MMV-supported projects
R&D areas of work
Next-generation medicines
Products for key populations
Working with regulators
Information for scientists
Call for proposals
TPPs & TCPs
Learning resources for discovery scientists
Project of the year award
Computational chemistry
Global health compound design webinars
R&D challenges
Access
Products & projects
Areas of work
Supporting introduction
Enhancing reach
Informing R&D
Gathering market intelligence
Product maps
Tool Kits
Injectable Artesunate tool kit
Artesunate rectal capsules tool kit
Seasonal Malaria Chemoprevention tool kit
The road to health impact
Access challenges
Partnering
Our partner network
The PDP model
Socially responsible agreements
Our clinical centre partners
Our donors
Current donors
Past donors
Donate to MMV
Our impact
Achievements
Real life stories
Better medicines for children
Malaria and COVID-19
About us
What we do
An overview of our work
Our strategic focus
Our history
People & governance
Staff bios
Staff map
Staff interviews
Board of Directors
MMV North America Board
Expert Scientific Advisory Committee
Access & Product Management Advisory Committee
Global Safety Board
Work with us
Jobs
RFPs/RFIs
MMV's internship programme
Policies
Diversity at MMV
Funding and expenditure
FAQs
Contact us
Malaria & medicines
Definitions and symptoms
Five species
Parasite lifecycle
Malaria facts & figures
Malaria treatment
History of antimalarials
Optimizing artemisinin production
Malaria online course
Newsroom
News & Press Releases
Audio
Media interviews
Films
Infographics
Interviews
Image slideshows
Publications
Events
MMV Open
Malaria
Libre
About Malaria
Libre
Participate in Malaria
Libre
Malaria
Libre
data repository
COVID Box
About the COVID Box
Request the COVID box
Supporting information
COVID Box terms and conditions
Pandemic Response Box
About the Pandemic Response Box
Request the Pandemic Response Box
Supporting information
Terms & conditions
Pathogen Box
About the Pathogen Box
Exploiting the Pathogen Box
Pathogen Box research
Supporting information
Terms & conditions
Malaria Box
About the Malaria Box
Malaria Box Research
Supporting information
Terms & conditions
Map of box orders
Follow-up guidelines
Open Source Drug Discovery
MMV Open Team
Contact us
Home
Newsroom
News & Press Releases
News & Press Releases
Filter
Category
All
News story
Press release
Topic
Access & product management
Donors
General
Open source
Partner
R&D
Search Terms
430 found
MMV deeply saddened by the loss of Prof. Ogobara Doumbo
11 Jun 2018
Australia renews commitment to MMV and R&D for malaria
08 Jun 2018
MMV partner Kelly Chibale in Fortune Greatest Leaders list 2018
30 Apr 2018
MMV’s contributions to malaria commended at MIM conference
27 Apr 2018
Major study confirms tolerability and high efficacy of 4 gold-standard malaria medicines, when used for repeated treatment over a 2 year period
29 Mar 2018
WHO provides first-ever approval for rectal artesunate product for severe malaria
27 Feb 2018
MMV welcomes Philip Welkhoff, new Malaria Program Director, BMGF
14 Feb 2018
MMV and DNDi deliver joint statement at WHO Executive Board
27 Jan 2018
MMV end-of-year review 2017
02 Jan 2018
WHO issues information note on correct use of rectal artesunate for severe malaria
18 Dec 2017
Unitaid awards MMV new supply side grant
08 Dec 2017
PLOS Medicine publishes New Malaria Eradication Road Map
01 Dec 2017
Two new MMV-supported research sites inaugurated in Ethiopia
30 Nov 2017
Two MMV partners receive international award
30 Nov 2017
Global malaria response “off track” in 2016
29 Nov 2017
GSK submits US regulatory application for single-dose tafenoquine for
Plasmodium vivax
malaria
28 Nov 2017
USAID renews support to MMV with new grant
09 Nov 2017
100 million vials of injectable artesunate distributed since 2010
06 Nov 2017
MMV backs training course for study coordinators
01 Nov 2017
MMV and Transaid partner to tackle severe malaria in Zambia
31 Oct 2017
MMV hosts international drug discovery meeting in Geneva
26 Oct 2017
Three vivax research teams awarded MMV Project of the Year 2016
10 Oct 2017
MMV discovery partners receive ASBMB awards
09 Oct 2017
KAF156 enters phase IIb combination studies
21 Aug 2017
Everything you always wanted to know about malaria and more
03 Aug 2017
Cipla launches quality-assured Rectal Artesunate Suppositories for severe malaria in young children
25 Jul 2017
Three MMV-supported antimalarials listed as essential medicines
16 Jun 2017
MMV and GSK announce positive headline phase III results showing single-dose tafenoquine reduces risk of relapse in patients with
Plasmodium vivax
malaria
12 Jun 2017
Dr Tedros Adhanom Ghebreyesus elected as the new Director-General of WHO
24 May 2017
MMV and partners launch “call to action” to G20 health ministers
22 May 2017
MMV launches new Severe Malaria Observatory
18 May 2017
MMV and Aga Khan Foundation Canada come together to tackle malaria in Mali
01 May 2017
New publication highlights efficacy of MMV048 against resistant strains of malaria
27 Apr 2017
New antimalarial compound treats and protects in a single dose
29 Mar 2017
MMV 4th in top 10 rare infectious disease drug developers
28 Mar 2017
Awa Marie Coll-Seck receives Best Minister Award
27 Feb 2017
MMV shines a light on malaria in Times Square
22 Feb 2017
RBM appoints new CEO
27 Jan 2017
MMV delivers statement at 140th session of the WHO Executive Board
27 Jan 2017
MMV welcomes the launch of the End Malaria Council
25 Jan 2017
MMV brings new partner Janssen Pharmaceuticals on board
19 Jan 2017
MMV end-of-year review 2016
22 Dec 2016
Swiss Malaria Group invites you to enter photo and video competition
17 Dec 2016
Cipla’s artesunate suppository first to be quality-assured by Global Fund
16 Dec 2016
World Malaria Report 2016 reveals improved malaria control for vulnerable but substantial gaps remain
13 Dec 2016
MMV partner GSK ranked first in the Access to Medicine Index – again
17 Nov 2016
MMV partner Prof. David Fidock wins the 2016 Advance Global Australian of the Year Award in Life Sciences
21 Oct 2016
MMV and Zydus join forces to develop new antimalarial
27 Sep 2016
First open source malaria publication describes new way to do drug discovery
14 Sep 2016
PLOS Pathogens
publishes the Malaria Box findings
28 Jul 2016
UCT-H3D, MMV and international partners identify second potent antimalarial candidate
27 Jul 2016
MMV awards seven endemic-region scientists Challenge Grants to ‘exploit the Pathogen Box’
25 Jul 2016
MMV and Novartis expand partnership
15 Jun 2016
Malaria community mourns the tragic loss of Dr Sylvia Meek
23 May 2016
Netherlands-based consortium teams up with MMV in world-leading malaria translational research programme
25 Apr 2016
MMV joins Swiss Malaria Group in Bern to commemorate World Malaria Day
25 Apr 2016
Pyramax® granules (pyronaridine-artesunate) for children added to WHO list of prequalified medicines
20 Apr 2016
Endemic-Region Challenge Grants of USD 50,000 each available to exploit the Pathogen Box
31 Mar 2016
MMV announces collaborative agreement with S Kant HEALTHCARE Ltd
10 Mar 2016
MMV welcomes WHO approval of 3-year shelf-life for antimalarial ASMQ
08 Mar 2016
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
next ›
last »